Silence Therapeutics (SLN) Proxy filing summary

Executive summary

• Definitive acquisition agreement with Merck KGaA announced October 19, 2026; closing expected in Q1 2027, subject to customary conditions.

• Q3 2026 cash and cash equivalents were $247.7 million, including $201.3 million in gross proceeds from an August public offering; net loss was $12.4 million vs. $21.0 million in Q3 2025.

Voting matters and shareholder proposals

• A transaction proxy statement and UK scheme explanatory statement are planned; securityholders were urged to review them and any related filings when available.

• Completion depends in part on required shareholder approvals and sanction by the High Court of Justice of England and Wales.

Board of directors and corporate governance

• Iain Ross signed the filing as Interim Principal Executive Officer and Chairman of the Board.

• Directors, certain executive officers and other employees may be deemed participants in the transaction-related proxy solicitation; additional interest details are expected in the transaction proxy statement.